Biolinq Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
102
- Latest Deal Type
-
Mezzanine
- Latest Deal Amount
-
$5.39M
- Investors
-
34
Biolinq General Information
Description
Developer of a biomonitoring health platform intended to improve metabolic health. The company's platform offers a skin-applied, minimally-invasive electrochemical biosensor through a potential of multiple analytes such as glucose, ketones, and lactate, and provides actionable metabolic health insights from multi-analyte wearable sensors, allowing patients with diabetes to monitor their blood glucose without the pain and hassle of traditional systems.
Contact Information
Website
www.biolinq.comCorporate Office
- 10260 Sorrento Valley Road
- San Diego, CA 92121
- United States
Corporate Office
- 10260 Sorrento Valley Road
- San Diego, CA 92121
- United States
Biolinq Timeline
Biolinq Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Mezzanine | 13-Sep-2024 | $5.39M | Completed | Generating Revenue | ||
| 13. Later Stage VC | 29-Aug-2024 | Completed | Generating Revenue | |||
| 12. Mezzanine | 26-Mar-2024 | Completed | Generating Revenue | |||
| 11. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 10. Later Stage VC | 19-Dec-2023 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 8. Later Stage VC (Series B) | 17-Oct-2022 | Completed | Clinical Trials - Phase 2 | |||
| 7. Grant | 01-Sep-2021 | Completed | Clinical Trials - Phase 2 | |||
| 6. Accelerator/Incubator | 01-Jun-2020 | $16.2M | Completed | Clinical Trials - Phase 2 | ||
| 5. Debt - PPP | 01-May-2020 | $16.2M | Completed | Clinical Trials - Phase 2 |
Biolinq Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-1 | ||||||||
| Series A | 10,487,367 | $0.000100 | $0.88 | $0.88 | 1x | $0.88 | 7.95% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Biolinq Comparisons
Industry
Financing
Details
Biolinq Competitors (5)
One of Biolinq’s 5 competitors is Senseonics, a Formerly VC-backed company based in Germantown, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Senseonics | Formerly VC-backed | Germantown, MD | ||||
| GlucoWise | Formerly Accelerator/Incubator backed | London, United Kingdom | ||||
| GlySens | Venture Capital-Backed | San Diego, CA | ||||
| GWave | Venture Capital-Backed | Tel Aviv, Israel | ||||
| DexCom | Formerly VC-backed | San Diego, CA |
Biolinq Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Biolinq Patents
Biolinq Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-D1035004-S1 | Wearable sensor | Active | 28-Feb-2023 | ||
| US-20240315614-A1 | Method for improved sensor sensitivity of a microneedle-based continuous analyte monitoring system | Pending | 02-Feb-2023 | ||
| US-20240008777-A1 | Sensor assembly of a microneedle array-based continuous analyte monitoring device | Active | 05-Jul-2022 | ||
| US-12070313-B2 | Sensor assembly of a microneedle array-based continuous analyte monitoring device | Active | 05-Jul-2022 | ||
| US-20240366125-A1 | Sensor assembly of a microneedle array-based continuous analyte monitoring device | Pending | 05-Jul-2022 | A61B5/1473 |
Biolinq Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Biolinq Investors (34)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Pegasus Tech Ventures | Corporate Venture Capital | Minority | ||
| Standish Spring Investments | Venture Capital | Minority | ||
| Venture Lab Niterra Group | Corporate Venture Capital | Minority | ||
| Bedford Bridge | Venture Capital | Minority | ||
| Able Partners | Venture Capital | Minority |
Biolinq FAQs
-
When was Biolinq founded?
Biolinq was founded in 2012.
-
Where is Biolinq headquartered?
Biolinq is headquartered in San Diego, CA.
-
What is the size of Biolinq?
Biolinq has 102 total employees.
-
What industry is Biolinq in?
Biolinq’s primary industry is Monitoring Equipment.
-
Is Biolinq a private or public company?
Biolinq is a Private company.
-
What is Biolinq’s current revenue?
The current revenue for Biolinq is .
-
How much funding has Biolinq raised over time?
Biolinq has raised $249M.
-
Who are Biolinq’s investors?
Pegasus Tech Ventures, Standish Spring Investments, Venture Lab Niterra Group, Bedford Bridge, and Able Partners are 5 of 34 investors who have invested in Biolinq.
-
Who are Biolinq’s competitors?
Senseonics, GlucoWise, GlySens, GWave, and DexCom are competitors of Biolinq.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
